Dattani Nikesh, Sayers Robert D, Bown Matthew J
Department of Cardiovascular Sciences, NIHR Leicester Cardiovascular Biomedical Research Unit and British Heart Foundation Cardiovascular Research Centre, University of Leicester, Leicester, UK.
Diab Vasc Dis Res. 2018 Sep;15(5):367-374. doi: 10.1177/1479164118780799. Epub 2018 Jun 6.
Diabetes mellitus appears to be negatively associated with abdominal aortic aneurysm; however, the mechanisms underlying this relationship remain poorly understood. The aim of this article is to provide a comprehensive review of the currently understood biological pathways underlying this relationship.
A review of the literature ('diabetes' OR 'hyperglycaemia' AND 'aneurysm') was performed and relevant studies grouped into biological pathways.
This review identified a number of biological pathways through which diabetes mellitus may limit the presence, growth and rupture of abdominal aortic aneurysms. These include those influencing extracellular matrix volume, extracellular matrix glycation, the formation of advanced glycation end-products, inflammation, oxidative stress and intraluminal thrombus biology. In addition, there is an increasing evidence to suggest that the medications used to treat diabetes can also limit the development and progression of abdominal aortic aneurysms.
The negative association between diabetes and abdominal aortic aneurysm is robust. Future studies should attempt to target the pathways identified in this review to develop novel therapeutic agents aimed at slowing or even halting aneurysm progression.
糖尿病似乎与腹主动脉瘤呈负相关；然而，这种关系背后的机制仍知之甚少。本文旨在全面综述目前所了解的这种关系背后的生物学途径。
对文献（“糖尿病”或“高血糖症”与“动脉瘤”）进行综述，并将相关研究归类为生物学途径。
本综述确定了糖尿病可能限制腹主动脉瘤的存在、生长和破裂的一些生物学途径。这些途径包括影响细胞外基质体积、细胞外基质糖基化、晚期糖基化终产物的形成、炎症、氧化应激和腔内血栓生物学的途径。此外，越来越多的证据表明，用于治疗糖尿病的药物也可以限制腹主动脉瘤的发展和进展。
糖尿病与腹主动脉瘤之间的负相关关系很显著。未来的研究应尝试针对本综述中确定的途径，开发旨在减缓甚至阻止动脉瘤进展的新型治疗药物。
